In this article (), which was published in the October 1, 2007 issue of Cancer Research (1), the corresponding author informed us that the same Mcl-1 Western blots were inadvertently duplicated in Fig. 4C and Fig. 3C. The corrected versions of both figures, and their corrected legends, appear below.
C, both U937/EV and U937/Mcl-1 cells were exposed to sorafenib (7.5 μg), TRAIL (75 ng/mL), or their combination for the indicated time intervals, and at the end cells were pelleted, lysed, and 30 μg of protein were separated by SDS-PAGE, blotted, and probed with the corresponding anti–Mcl-1 and tubulin (to ensure equivalent loading and transfer) antibodies. The results of a representative study are shown; two additional experiments yielded similar results.
C, both U937/EV and U937/Mcl-1 cells were exposed to sorafenib (7.5 μg), TRAIL (75 ng/mL), or their combination for the indicated time intervals, and at the end cells were pelleted, lysed, and 30 μg of protein were separated by SDS-PAGE, blotted, and probed with the corresponding anti–Mcl-1 and tubulin (to ensure equivalent loading and transfer) antibodies. The results of a representative study are shown; two additional experiments yielded similar results.
C, expression levels of Mcl-1 were determined in whole lysates of U/casp8DN and U/EV cells exposed to sorafenib (7.5 μmol/L), TRAIL (75 ng/mL), or the combination (S24→T) as indicated; blots were subsequently stripped and probed with a tubulin antibody to ensure equivalent loading and transfer. Analysis of conformational change in Bax and Bak was done using extracts from the same cells; lysates were prepared, immunoprecipitated with either anti–Bak-Ab1– or anti–Bax-6A7–specific antibodies, followed by immunoblotting with anti-Bak or anti-Bax antibodies, respectively, as described in Materials and Methods. Each lane was loaded with 30 μg of protein; IgG controls confirm equivalent loading and transfer. The results of a representative study are shown; two additional experiments yielded similar results.
C, expression levels of Mcl-1 were determined in whole lysates of U/casp8DN and U/EV cells exposed to sorafenib (7.5 μmol/L), TRAIL (75 ng/mL), or the combination (S24→T) as indicated; blots were subsequently stripped and probed with a tubulin antibody to ensure equivalent loading and transfer. Analysis of conformational change in Bax and Bak was done using extracts from the same cells; lysates were prepared, immunoprecipitated with either anti–Bak-Ab1– or anti–Bax-6A7–specific antibodies, followed by immunoblotting with anti-Bak or anti-Bax antibodies, respectively, as described in Materials and Methods. Each lane was loaded with 30 μg of protein; IgG controls confirm equivalent loading and transfer. The results of a representative study are shown; two additional experiments yielded similar results.
The online version of the article has been corrected and no longer matches the print. The authors regret this error.
RSS Feeds